{'fraction_non_alphanumeric': 0.04535637149028078, 'fraction_numerical': 0.027357811375089993, 'mean_word_length': 4.323754789272031, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MO840: A Survey on the Impact of Pruritus Associated With Chronic Kidney Disease (CKD-AP) In the Quality of Life of Patients Undergoing Haemodialysis in Spain


 
 
 Chronic kidney disease (CKD) patients can be affected by pruritus. In Spain, CKD associated pruritus (CKD-aP) affects 60% of CKD patients on haemodialysis (HD). CKD-aP severely impacts in physical and mental health of patients, resulting in sleep disturbance, depressed mood, increased risk of infection and a low quality of life [1]. In Spain, there is a lack of data regarding CKD-aP patient's quality of life (QoL). The aim of the study is to determine how CKD-aP affects the HD patients’ QoL in Spain.
 
 
 
 The study was structured in two phases: The first phase involved the design and the validation (by a multidisciplinary panel of 9 experts) of a survey to assess CDK-aP patient's QoL. The second phase consisted in sending the survey to CKD patients and subsequent results analysis.
 
 
 
 The survey was structured in 10 domains with 25 questions that collected relevant aspects of the CKD-aP patients’ QoL.
 A total of 189 HD patients answered the survey, 97 (51%) of whom had CKD-aP. The main results are showed in Table 1.
 CKD-aP HD patients reported a health status significantly lower than HD patients without pruritus (mean = 46 versus 53 out of 100, respectively, P-value = 0.02). Moreover, the health status worsened when increasing severity of pruritus (mild = 51/100; moderate = 48/100; severe = 32/100). Out of 10, 6 CKD-aP patients suffer from it always or sometimes a day. A total of 30% of patients reported pruritus throughout the day, while 29% suffer from it at night. 39% of CKD-aP patients, of which 39% have severe pruritus and 62% moderate, reported having difficulty falling asleep sometimes a week or more. A total of 44% of patients experienced irritability once a week or more, 32% frustration, 21% distress, 11% depression and 7% embarrassment. In addition, pruritus limits patients’ daily and social activities (12% patients were limited once a week or more), preventing them from doing sports, housework, going to restaurants and/or engaging in cultural activities. It also alters patients’ cognitive function, leading to a lack of concentration and/or confusion (22% patients had an altered cognitive function once a week or more). 10% of patients had infections or fistula damage due to scratching. 62% of CKD-aP patients were not treated for pruritus, and of those treated, 47% were dissatisfied with their treatment.
 
 
 
 This study shows that CKD-aP is a distressing condition with a huge impact in CKD HD patients’ QoL in Spain. However, there is an unmet need in terms of treatment, meaning that new treatments for CKD-aP are necessary to improve patients’ QoL.
